Danish pharmaceutical firm Novo Nordisk has elected Brian Daniels as a new member of its board of directors.
He brings over 20 years of pharmaceutical management expertise to the board, having served as director of immunology at MSD and vice president of immunology then senior vice president of global development and medical affairs at Bristol-Myers Squibb.
Currently, Daniels serves as a senior advisor to the Boston Consulting Group and a venture partner for 5AM Venture Management, both of which are based in the US.
In a statement, Novo Nordisk’s board of directors said it had recommended Daniels because of “his extensive experience in clinical development, medical affairs and corporate strategy across a broad range of therapeutic areas”.
Novo Nordisk also announced the re-election of Goran Ando, Jeppe Christiansen, Bruno Angelici, Sylvie Gregoire, Liz Hewitt and Mary Szela to the board of directors.
Source: PMLive
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
